Transcenta Holding (HKSE:06628) Equity-to-Asset : 0.61 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Transcenta Holding Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Transcenta Holding's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$1,124.00 Mil. Transcenta Holding's Total Assets for the quarter that ended in Dec. 2023 was HK$1,852.10 Mil. Therefore, Transcenta Holding's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.61.

The historical rank and industry rank for Transcenta Holding's Equity-to-Asset or its related term are showing as below:

HKSE:06628' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.54 Med: 0.61 Max: 0.77
Current: 0.61

During the past 5 years, the highest Equity to Asset Ratio of Transcenta Holding was 0.77. The lowest was -0.54. And the median was 0.61.

HKSE:06628's Equity-to-Asset is ranked worse than
54.81% of 1558 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:06628: 0.61

Transcenta Holding Equity-to-Asset Historical Data

The historical data trend for Transcenta Holding's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transcenta Holding Equity-to-Asset Chart

Transcenta Holding Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

-0.54

-0.39

0.77

0.69

0.61

Transcenta Holding Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial				0.77	0.73	0.69	0.64	0.61

Competitive Comparison of Transcenta Holding's Equity-to-Asset

For the Biotechnology subindustry, Transcenta Holding's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transcenta Holding's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transcenta Holding's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Transcenta Holding's Equity-to-Asset falls into.

Transcenta Holding Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Transcenta Holding's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	1124.003	/	1852.095
	=	0.61

Transcenta Holding's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	1124.003	/	1852.095
	=	0.61

Transcenta Holding (HKSE:06628) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Transcenta Holding Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Transcenta Holding's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Transcenta Holding (HKSE:06628) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transcenta Holding Ltd (HKSE:06628) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

B6-501, 218 Xinghu Street, Biobay, Suzhou, CHN, 215123

Website

https://www.transcenta.com

Transcenta Holding Ltd is a clinical stage biopharmaceutical company with fully integrated capacities in discovery, research, development and manufacturing. It is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Geographically the company operates in China (the "PRC") and the USA.

Executives

Qian Xueming	2101 Beneficial owner
Shi Xiaohong	2501 Other
Lav Corporate Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Gp Iii, L.p.	2201 Interest of corporation controlled by you
Lav Biosciences Fund Iii, L.p.	2101 Beneficial owner
Shi Yi	2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited	2102 Investment manager
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited
Tls Beta Pte. Ltd.
Hsbc Trust Company (delaware), N.a.	2301 Trustee
Success Link International L.p.	2101 Beneficial owner
Temasek Holdings (private) Limited
Lav Vitality Limited	2101 Beneficial owner
Zhong Guo Guo You Qi Ye Jie Gou Tiao Zheng Ji Jin Gu Fen You Xian Gong Si	2501 Other

Transcenta Holding (HKSE:06628) Headlines

No Headlines